Efficacy and safety of conivaptan, a vasopressin via- and v2-receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia

被引：0
|
作者：
Verbalis, Joseph G. [1 ]
Rosansky, Steven [1 ]
Wagoner, Lynne E. [1 ]
McNutt, Bruce [1 ]
Yan, Bo [1 ]
机构：
[1] Georgetown Univ, Washington, DC USA
来源：
CHEST | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：562S / 562S
页数：1
相关论文
共 50 条
  • [1] Efficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Bisaha, JG
    Smith, N
    CIRCULATION, 2004, 110 (17) : 723 - 723
  • [2] Efficacy and safety of conivaptan, an arginine vasopressin antagonist, in patients with hypervolemic hyponatremia
    Goldsmith, Steven R.
    Verbalis, Joseph G.
    Smith, Neila
    Barve, Abhijit
    Andoh, Masakazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 98A - 98A
  • [3] Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia
    Annane, Djillali
    Decaux, Guy
    Smith, Neila
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2009, 337 (01): : 28 - 36
  • [4] Efficacy and safety of oral conivaptan:: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Ghali, Jalal K.
    Koren, Michael J.
    Taylor, James R.
    Brooks-Asplund, Esther
    Fan, Kaisheng
    Long, Walker A.
    Smith, Neila
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2145 - 2152
  • [5] Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial.
    Verbalis, J. G.
    Ghali, J. K.
    Gross, P.
    Long, W. A.
    Smith, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 480S - 480S
  • [6] Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia - efficacy, safety, and pharmacokinetics
    Palmer, Biff F.
    Rock, Amy D.
    Woodward, Emily J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 339 - 351
  • [7] Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia A Meta-Analysis
    Zhang, Xiangyun
    Zhao, Mingyi
    Du, Wei
    Zu, Dongni
    Sun, Yingwei
    Xiang, Rongwu
    Yang, Jingyu
    MEDICINE, 2016, 95 (15)
  • [8] Pharmacokinetics of Conivaptan Hydrochloride, a Vasopressin V1A/V2-Receptor Antagonist, in Patients With Euvolemic or Hypervolemic Hyponatremia and With or Without Congestive Heart Failure From a Prospective, 4-Day Open-Label Study
    Mao, Zhongping Lily
    Stalker, Dennis
    Keirns, James
    CLINICAL THERAPEUTICS, 2009, 31 (07) : 1542 - 1550
  • [9] Conivaptan, a novel arginine vasopressin antagonist, increased serum sodium concentration in patients with heart failure and euvolemic or hypervolemic hyponatremia
    Ghali, JK
    Verbalis, JG
    Gross, P
    Long, WA
    Smith, N
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 62A - 62A
  • [10] Hyponatremia correction with an oral vasopressin V2-receptor antagonist
    Al-Awqati, Qais
    KIDNEY INTERNATIONAL, 2007, 71 (04) : 288 - 288
12345